HCL2025 Researcher Profile: Dr. Reshmi Parameswaran, Case Western Reserve University School of Medicine
The HCL2025 research initiative is a collaboration of the Hairy Cell Leukemia Foundation and The Leukemia & Lymphoma Society to identify new and better therapies in hairy cell leukemia, and ultimately improve patient outcomes.
Our HCL2025 Profile Series will highlight the outstanding investigators whose discoveries could pave the way for new treatment options in HCL.
Today, we're highlighting Dr. Reshmi Parameswaran from Case Western Reserve University School of Medicine. Her research in HCL is looking at B cell activating factor (BAFF) CAR-T as a potentially effective therapeutic strategy for hairy cell leukemia.
Dr. Parameswaran completed her post-doctoral fellowship at Children’s Hospital Los Angeles, where she explored the role of BAFF in pediatric acute lymphoblastic leukemia (ALL). She was the first to identify the expression of BAFF receptor in ALL cells.
Case Western University School of Medicine is one of 53 Comprehensive Cancer Centers designated by the National Cancer Institute (NCI) for their work and research.
Check out Dr. Parameswaran's profile at Case Western here. >>
